Unum Therapeutics - So Far, So Good...

(RTTNews) - It's been a little over 4 months since this clinical-stage biopharmaceutical company debuted on the NASDAQ, and its shares touched a new high yesterday.

The company in focus is Unum Therapeutics Inc. (UMRX), developing novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer.

Unum's product candidates are composed of antibody-coupled T cell receptor (ACTR) cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development to target different tumor types.

The most advanced product candidate in the pipeline is ACTR087 used in combination with Rituximab, being tested in adult patients with CD20 relapsed or refractory non-Hodgkin lymphoma in an ongoing phase I clinical trial called ATTCK-20-2.

Initial results from the ATTCK-20-2 trial, reported last November, showed that out of the 6 evaluable patients, ACTR087 at the first dose level used in combination with Rituximab induced two complete responses and one partial response. No adverse events or cytokine-release syndrome or neurotoxicity were observed in the study.

Results of 6 evaluable patients from the second dose level of this trial were reported in March of this year, which revealed three partial responses. Dose-limiting toxicities were observed in three patients within this cohort.

In May of this year, the Company initiated a cohort expansion phase of the ATTCK-20-2 trial evaluating safety and anti-lymphoma activity of ACTR087 at the preliminary recommended phase 2 dose (RP2D) level used in combination with Rituximab in patients with CD20 relapsed or refractory non-Hodgkin lymphoma.

Unum expects to report updated data, including preliminary data from this cohort expansion phase of the ATTCK-20-2 trial, in the fourth quarter of 2018.

A phase II clinical trial exploring ACTR087 used in combination with Rituximab in adult patients with relapsed or refractory non-Hodgkin lymphoma who received prior CD19 CAR-T therapy is also being planned.

Next in the pipeline is ACTR707 used in combination with Rituximab in patients with CD20+ relapsed or refractory non-Hodgkin lymphoma, under a phase I trial, dubbed, ATTCK-20-03.

Enrollment in the first dose level of this ongoing dose escalation study has been completed, and preliminary data from the trial are expected in the fourth quarter of 2018.

The Company intends to file an IND for ACTR707 in combination with Trastuzumab for the treatment of patients with HER2+ advanced cancers in the second half of 2018.

Another ongoing phase I trial of the Company is ATTCK-17-01, which is evaluating ACTR087 in combination with Seattle Genetics' SEA-BCMA in patients with relapsed or refractory multiple myeloma.

SEA-BCMA is an antibody empowered using Seattle Genetics' proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody effector functions. Unum has a strategic cancer immunotherapy collaboration with Seattle Genetics that was signed in June 2015.

Initial data from the phase I trial of ACTR087 used in combination with SEA-BCMA is also expected in the fourth quarter of 2018.

The Company was added to the Russell 3000 Index on June 25, 2018, following the Russell US Indices' annual reconstitution.

Key Numbers...

*Accumulated deficit: $64.3 million * Cash on hand: $32.4 million Shares Outstanding: 29.84 million Float : 11.6 million

(*As of March 31, 2018)

In addition, the Company has approximately $66.8 million in net proceeds raised from its IPO in April 2018, $5.0 million from the concurrent private placement, and available borrowings under its loan and security agreement of $15.0 million.

Unum went public on the Nasdaq Global Select Market on March 29, 2018, offering its shares at a price of $12 each. The stock touched a new high of $17.66 in intraday trading yesterday (Aug .7), before closing at $16.67, up 1.34%.